Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


About us

MEDtalks is an independent multidisciplinary Internet TV channel for medical professionals. Interviews with scientists, research results and accredited refresher courses will be published on this website for registered doctors and nurses.


Login Register

Our channels

Featured Articles

  • Save
Quarterly focus 12/09/2018

E-learning: Quarterly Focus on Genitourinary Cancer | RCC

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this second episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Renal Cell Carcinoma from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Prof. John Haanen, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam Hans Westgeest, MD, medical oncologist, Amphia Ziekenhuis, Breda Astrid van der Veldt, MD, PhD, medical oncologist, Erasmus MC, Rotterdam Program: Invited speaker: Kathleen Mahoney, MD, PhD, medical oncologist, Beth Israel Deaconess Medical Center, Boston Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma N Engl J Med 378, 2018 Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Nature Medicine 24, 2018

00:08:11
  • Save
Congresnieuws 27/06/2018

ASCO 2018 Rechallenge with bevacizumab in ovarian cancer

Dr. Sandro Pignata, oncologist and president of the Multicentre Italian Trial in Ovarian cancer (MITO) group, explains the results of the MITO 16b trial. This study evaluated whether the addition of bevacizumab to a platinum-based chemotherapy prolongs survival for recurrent ovarian cancer patients who had already received it during first line.

  • Save
Quarterly focus 07/06/2018

E-learning: Quarterly Focus on Hemato-Oncology | Highlights in AML 2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Three high-impact, recent international publications on two main topics in AML will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The studio expert panel consists of: Prof. Gert Ossenkoppele, MD, PhD, hematologist, VUmc Amsterdam, The Netherlands Bas Wouters, MD, PhD, hematologist, ErasmusMC Rotterdam, The Netherlands Peter Valk, PhD, molecular biologist in hematology, ErasmusMC Rotterdam, The Netherlands Live video guests: Courtney Dinardo, MD, hemato-oncologist, MD Anderson Cancer Center, Houston, US Eytan Stein, MD, hemato-oncologist, MSKCC, New York, US Prof. Christian Thiede MD, PhD, professor in molecular hematology, Universitätsklinikum Dresden, Germany

00:06:50
  • Save
Congresnieuws 27/06/2018

ASCO 2018 Results of the TAILORx trial

Joseph Sparano, oncologist at Montefiore Medical Center, explains the results of the TAILORx trial, which he presented during the plenary session at ASCO 2018. This trial attempted to incorporate a gene expression test into clinic decision making for hormone receptor positive breast cancer.

00:39:40
  • Save
Congresnieuws 22/03/2018

ASCO GU 2018: Renal Cell Carcinoma News Program

This year the ASCO Genitourinary Cancers Symposium took place in San Francisco from February 8th - 10th. In this Renal Cell Carcinoma News Program, we focus on the highlights for RCC at this congress. Moderator Catherine Hood and a panel of international experts discuss the following topics: Adjuvant systemic therapy Cabozantinib in the first line treatment of metastatic RCC The NIVOREN trial that investigates nivolumab in a ‘real world setting’ Combination treatments with VEGF and PD1/PD-L1 inhibition Advances in treatment for papillary RCC Speakers: Prof. Joaquim Bellmunt, MD, medical oncologist, Dana-Farber/Brigham and Women's Cancer Center, Boston Daniel George, MD, medical oncologist, Duke Cancer Center, Durham Jeanny Aragon-Ching, MD, medical oncologist, Inova Fairfax hospital, Fairfax Sumanta Pal, MD, medical oncologist, City of Hope Comprehensive Cancer Center, Duarte Moderator: Catherine Hood

  • Save
Quarterly focus 22/03/2018

E-learning: Quarterly Focus on Breast Cancer

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not have always sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks.eu/OncologyTV has developed a new program format, the 'Quarterly Focus', which brings together an expert panel and the authors of relevant, selected publications in an innovative way to explain and discuss the new data. Two pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the unique possibility to gain more insight into the selected publications and to interact with the expert panel and the authors. The expert panel consists of: Gabe Sonke, MD, Ph.D, medical oncologist, NKI-AVL Amsterdam, Netherlands Ester Siemerink, MD, Ph.D, medical oncologist, Ziekenhuis Groep Twente, Hengelo/Almelo, Netherlands Rianne Oosterkamp, MD, medical oncologist, Haaglanden Medisch Centrum, Den Haag, Netherlands Invited speakers: Prof. George Sledge, MD, medical oncologist Stanford University School of Medicine, California, US MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy J Clin Oncol, 2017 Prof. Laura van 't Veer, molecular biologist UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades JAMA Oncol, 2017

00:06:35
  • Save
Congresnieuws 22/03/2018

ASCO GU 2018: PROs and HRQoL of LATITUDE

Dr. Kim Chi, medical oncologist at the BC Cancer Agency in Vancouver, summarizes the results of the LATITUDE trial and the recently published patient-reported outcomes and health-related quality of life.

Upcoming live Broadcasts

  • Save
Quarterly focus 16/08/2018

November 6th: Quarterly Focus on GU | Bladder Cancer

In each Quarterly Focus MEDtalks Oncology brings you the unique opportunity to gain more insight into two pivotal publications on Genitourinary Cancer. In the third episode (watch episode 1 on prostate cancer and episode 2 on renal cell carcinoma on-demand) two international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. During the live broadcast on Tuesday November 6th 8.30-9.30 PM CEST you have the possibility to interact with our expert panel and the authors and ask them your questions. The expert panel consist of: Michiel van der Heijden, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam Prof. Fred Witjes, MD, PhD, urologist, Radboudumc, Nijmegen Sjoukje Oosting, MD, PhD, medical oncologist, UMCG, Groningen Provisional program: Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis  European Urology 73, 2018 Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial Lancet 391, 2018 Sign up for this live program

This website uses cookies to improve your experience of this website. You can choose to block cookies. However, some cookies are essential for the proper functioning of the website. By clicking "Accept" button, you confirm our cookie policy to have read and accepted. You can disable these cookies via your browser, see for example this explanation by the Consumers for explanation

On acceptance: use all cookie settings
On denial: use only necessary cookies